Product Description
Mechanisms of Action: ADRA1 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Bulgaria | Canada | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|